Atom Therapeutics Announces Abstract for Its Phase 2a Gout Study Accepted for American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia

PRESS RELEASE

Atom Therapeutics Announces Abstract for Its Phase 2a Gout Study Accepted for American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia

Gout is genetic disease with a surging patient population worldwide

Jiangsu, China—September, 13, 2022 – Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today the American College of Rheumatology (ACR) has accepted Atom’s abstract on a Phase 2a clinical trial of its small molecule URAT1 inhibitor for treatment of chronic gout. The abstract will be featured in an Ignite Talk presentation at ACR’s annual meeting, Convergence 2022, in Philadelphia, PA, Nov. 10-14.

The abstract titled, “A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia,” will be presented by Marc Gurwith, M.D., J.D., Atom’s Chief Medical Officer. Dr. Gurwith’s Ignite Talk is scheduled for Sunday, Nov.13 at 10 am. U.S. Eastern Time. A virtual poster presentation will be in Poster Session D on Monday, Nov. 14, from 1 pm. to 3 pm. U.S. Eastern Time.

“We are very pleased that ACR has accepted our poster and given us a presentation opportunity,” said Atom CEO, President and Founder William Shi, Ph.D. “Patients with chronic gout currently have few treatment options that are effective, safe and well tolerated.”

Gout is a genetic disease which is mistakenly associated with over-indulgence as its cause. It is the most common inflammatory arthritis and occurs when uric acid levels in the blood exceed 7 mg/dl, a condition known as hyperuricemia. The excess uric acid levels lead to formation of crystals in and around the joints and other soft tissues, triggering sudden flaring of inflammation and unleashing excruciating pain.

The disease has a large and growing patient population in the U.S., Europe, Asia and Latin America. More than 9 million people in the U.S. suffer from gout and as many as 55 million worldwide. A recent study also showed African Americans can be more vulnerable to gout.

About Atom Therapeutics
Hangzhou Atom Therapeutics Co., Ltd., is a fast-growing innovative drug company focused on development of best in class small molecule therapeutics for treatment of inflammatory and metabolic diseases. The company’s lead product, ABP-671, is in clinical development for treatment of chronic gout. For more information please visit: atombp.com